MX2009009415A - Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina. - Google Patents
Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.Info
- Publication number
- MX2009009415A MX2009009415A MX2009009415A MX2009009415A MX2009009415A MX 2009009415 A MX2009009415 A MX 2009009415A MX 2009009415 A MX2009009415 A MX 2009009415A MX 2009009415 A MX2009009415 A MX 2009009415A MX 2009009415 A MX2009009415 A MX 2009009415A
- Authority
- MX
- Mexico
- Prior art keywords
- histamine
- receptor
- modulators
- tetrahydroisoquinoline compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
Ciertos compuestos sustituidos de tetrahidroisoquinolina son moduladores del receptor H3 de la histamina, útiles en el tratamiento de enfermedades mediadas por el receptor H3 de la histamina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89232407P | 2007-03-01 | 2007-03-01 | |
PCT/US2008/055285 WO2008109336A1 (en) | 2007-03-01 | 2008-02-28 | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009009415A true MX2009009415A (es) | 2009-09-11 |
Family
ID=39488217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009415A MX2009009415A (es) | 2007-03-01 | 2008-02-28 | Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090099158A1 (es) |
EP (1) | EP2125741A1 (es) |
JP (1) | JP2010520217A (es) |
KR (1) | KR20090127307A (es) |
CN (1) | CN101668746A (es) |
AU (1) | AU2008223145A1 (es) |
BR (1) | BRPI0808525A2 (es) |
CA (1) | CA2679735A1 (es) |
MX (1) | MX2009009415A (es) |
RU (1) | RU2009136330A (es) |
WO (1) | WO2008109336A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
EA021119B1 (ru) * | 2008-04-23 | 2015-04-30 | Райджел Фармасьютикалз, Инк. | Карбоксамидные соединения для лечения метаболических расстройств |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
EP2429296B1 (en) * | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
JP5739415B2 (ja) * | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用 |
MX2011011901A (es) * | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
AR081498A1 (es) * | 2010-05-11 | 2012-09-19 | Sanofi Aventis | Derivados de n-alquil -y n-acil-tetrahidroisoquinolina sustituidos, preparacion y su uso terapeutico de los mismos |
CN102260265B (zh) * | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
AR092211A1 (es) * | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
EP3204359B1 (en) * | 2014-10-08 | 2020-07-01 | UCB Biopharma SRL | Tetrahydroisoquinoline derivatives |
AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
JP6908623B2 (ja) | 2016-04-13 | 2021-07-28 | ユーシービー バイオファルマ エスアールエル | テトラヒドロイソキノリン誘導体 |
WO2017201683A1 (en) * | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists |
WO2019134985A1 (en) * | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
BR112021022379A2 (pt) | 2019-07-01 | 2022-03-08 | UCB Biopharma SRL | Derivado de tetraidroisoquinolina substituído como um modulador alosterico d1 positivo |
US20220259179A1 (en) | 2019-07-01 | 2022-08-18 | UCB Biopharma SRL | A Substituted Tetrahydroisoquinoiline Derivative as a D1 Positive Allosteric Modulator |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980703107A (ko) | 1995-03-17 | 1998-10-15 | 후지야마 아키라 | N-아실피페리디닐카보닐아미노카복실산 및 당단백질 IIB/IIa 길항제와 피브리노겐-혈소판 결합 억제제로서의 이의 용도 |
GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
US20060167046A1 (en) | 2002-09-18 | 2006-07-27 | Eli Lilly And Company Patent Division | Histamine h3 receptor antagonists, preparation and therapeutic uses |
WO2005108367A1 (en) | 2004-05-03 | 2005-11-17 | Envivo Pharmaceuticals, Inc. | Compounds for treatment of neurodegenerative diseases |
US20060194837A1 (en) | 2004-12-17 | 2006-08-31 | Carruthers Nicholas I | Tetrahydroisoquinoline compounds |
PT1899334E (pt) | 2005-06-17 | 2008-11-06 | Janssen Pharmaceutica Nv | Compostos de naftiridina |
CA2612495A1 (en) | 2005-06-17 | 2006-12-28 | Janssen Pharmaceutica N.V. | Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders |
-
2008
- 2008-02-28 AU AU2008223145A patent/AU2008223145A1/en not_active Abandoned
- 2008-02-28 BR BRPI0808525-0A patent/BRPI0808525A2/pt not_active Application Discontinuation
- 2008-02-28 US US12/039,162 patent/US20090099158A1/en not_active Abandoned
- 2008-02-28 CA CA002679735A patent/CA2679735A1/en not_active Abandoned
- 2008-02-28 WO PCT/US2008/055285 patent/WO2008109336A1/en active Application Filing
- 2008-02-28 KR KR1020097020397A patent/KR20090127307A/ko not_active Application Discontinuation
- 2008-02-28 RU RU2009136330/04A patent/RU2009136330A/ru unknown
- 2008-02-28 MX MX2009009415A patent/MX2009009415A/es unknown
- 2008-02-28 CN CN200880014049A patent/CN101668746A/zh active Pending
- 2008-02-28 JP JP2009551849A patent/JP2010520217A/ja not_active Withdrawn
- 2008-02-28 EP EP08730960A patent/EP2125741A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN101668746A (zh) | 2010-03-10 |
US20090099158A1 (en) | 2009-04-16 |
EP2125741A1 (en) | 2009-12-02 |
BRPI0808525A2 (pt) | 2014-08-19 |
CA2679735A1 (en) | 2008-09-12 |
RU2009136330A (ru) | 2011-04-10 |
AU2008223145A1 (en) | 2008-09-12 |
KR20090127307A (ko) | 2009-12-10 |
JP2010520217A (ja) | 2010-06-10 |
WO2008109336A1 (en) | 2008-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009009415A (es) | Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina. | |
MY146506A (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
UA96424C2 (ru) | Циклопропил амины как модуляторы н3 рецепторов гистамина | |
AP2960A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
AP2011005637A0 (en) | Carbazole compounds and therapeutic uses of the compounds. | |
EP2365815A4 (en) | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER | |
UA95247C2 (ru) | Пиримидиновые соединения как модуляторы рецептора серотонина | |
MX2009012228A (es) | Compuesto de triazolil aminopirimidina. | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
MX2009007336A (es) | Indazoles substituidos con 5-furopiridinona. | |
IL193479A0 (en) | Modulators of muscarinic receptors | |
MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
MY158253A (en) | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor | |
IL205137A0 (en) | 5-cyanothienopyridines for the treatment of tumours | |
EP2207555A4 (en) | NOVEL COMPOUNDS FOR THE TREATMENT OR MITIGATION OF OEDEMES, AND METHODS OF USE THEREOF | |
MX2009009364A (es) | Compuestos de indol y benzotiofeno como moduladores del receptor de histamina h3. | |
EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения | |
UA96574C2 (ru) | Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции | |
WO2008124524A3 (en) | Aryl sulfonamide compounds as modulators of the cck2 receptor | |
GB0508988D0 (en) | Organic compounds | |
ZA200705490B (en) | Substituted benzimidazoles for treatment of histomoniasis | |
UA95803C2 (ru) | Замещенные пиридиламидные соединения как модуляторы гистаминового н3-рецептора | |
UA29848U (uk) | Застосування системної реконструктивної терапії як способу лікування мігрені | |
TW200744607A (en) | Pyrimidine compounds as serotonin receptor modulators |